🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Controversy remains the major issue for combining radiotherapy with immunotherapy. Please see our recent publication in Lancet Oncology led by working group sponsored by NCI. My personalized Share Link: authors.elsevier.com/c/1kiL65EIIgPe…

Surgery vs SBRT . Age old debate. Can IO add to SBRT ? Nice conclusion summary of current situation. M. Bolton Jonathan Spicer MD PhD ESMO - Eur. Oncology #ELCC25

Induction chemo/IO followed by local TX is the trend for stage III NSCLC: 20-30% pCR, up to 50% MPR Surgery vs Radiotherapy? Non-invasive RT could achieve similar OS with better side effects: randomized study? First, Optimizing RT: 60 Gy in 15 FX vs chemo/RT 60 Gy in 30 FX

Dr Amol Akhade Jeff Ryckman M. Bolton Jonathan Spicer MD PhD ESMO - Eur. Oncology There’s actually a 4th longitudinal comparison study to add to the slide deck for next time. Andrea R. Filippi

The proposed study below would benefit from a 3rd arm of chemoimmunotherapy -> 60/15 without concurrent anything. ascopubs.org/doi/pdfdirect/…

Great to see first outputs from ESTRO-EORTC ReCare chigh-dose #reirradiation cohort - such data are sorely needed! Jonas Willmann presented characteristics for first 290 patients #ESTRO25; primarily thoracic & pelvic cancers. Patient enrolment closing in on 500 patients! #radonc

Promising result! Why not consider (lower dose SIB) hypofractionated nodal RT as well with primary SBRT? #ESTRO2025 #lcsm Drew Moghanaki Percy Lee MD

Hella Sand looked at rigid v deformable reg for lung #reirradiation. Both performed well, with good inter-centre consistency, but less variation for DIR, especially for cumulative max dose. Results have driven recommendations in the CURE Lung reRT trial #radonc #medphys #ESTRO25

🚀🔥⚡️ First RAPID-RT analysis at #ESTRO25: real-world data & rapid-learning show promising survival benefit with cardiac avoidance in lung RT. A scalable path to refine practice when RCTs aren’t feasible. Smart science, smarter care.

For 4-10 brain met, HA-WBRT reduced depression.

A protonterapia é xa unha realidade en marcha. Hoxe presentamos os primeiros 4 profesionais do cadro de persoal do Centro de Protonterapia de Galicia e iniciamos o plan de formación especializada. Un proxecto colectivo que nos sitúa á cabeza da vangarda oncolóxica.

Just catching up on some of the ESTRO25 sessions I couldn'get to. Very nice presentation from Dr Zeno Gouw from the NKI BD RT in LS-SCLC in patients <70 years is associated with superior outcomes

How did the Thora study acheive superior outcomes with higher dose RT in LS-SCLC with little increase in oesophageal toxicity? At #ESTRO25 this presentation suggests that keeping the overall treatment time short might be the key factor Should 60Gy BD over 4 weeks be a new SOC?

Recuerda ⬇️

📣New advance in neuro-oncology! OncoAlert PET RANO BM 1.0 criteria standardize #brainmetastases assessment using amino acid PET, enhancing clinical trials & patient care. Read more: 📖 Nature Medicine #btsm nature.com/articles/s4159…

Re-irradiation is common but challenging in lung cancer. ARS just published: American Radium Society™ Appropriate Use Criteria Systematic Review and Guidelines on Reirradiation for Non-small Cell Lung Cancer Executive Summary. My personalized Share Link: authors.elsevier.com/c/1l3k51Hx52Ni…

Real-World Analysis of Treatment Patterns in Limited-Stage Small Cell Lung Cancer: Implications for Clinical Practice. pubmed.ncbi.nlm.nih.gov/40313077/?s=09

Most viewed this week from JAMA Oncology: Combining immune checkpoint inhibitors with chemotherapy in the first line of treatment for older adults with non–small cell lung cancer can delay mortality but increases the risk of severe adverse events. ja.ma/3GZhA5x

Neoadjuvant PD-1/PD-L1 blockade combined with chemotherapy improved pathological response rates and surgical resectability in patients with T4 and/or N2-N3 stage III NSCLC. ja.ma/43beXGr

Outcomes After Radiation for Oligoprogressive Disease Sites in Patients With EGFR-Mutant Lung Cancer Treated With Osimertinib | JCO Precision Oncology ascopubs.org/doi/abs/10.120…